EP0454898A1 - Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten - Google Patents

Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten Download PDF

Info

Publication number
EP0454898A1
EP0454898A1 EP90119607A EP90119607A EP0454898A1 EP 0454898 A1 EP0454898 A1 EP 0454898A1 EP 90119607 A EP90119607 A EP 90119607A EP 90119607 A EP90119607 A EP 90119607A EP 0454898 A1 EP0454898 A1 EP 0454898A1
Authority
EP
European Patent Office
Prior art keywords
glycosaminoglycan
protein
modified
modified protein
reducing terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP90119607A
Other languages
English (en)
French (fr)
Other versions
EP0454898B1 (de
Inventor
Katsukiyo Sakurai
Kyosuke Miyazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Publication of EP0454898A1 publication Critical patent/EP0454898A1/de
Application granted granted Critical
Publication of EP0454898B1 publication Critical patent/EP0454898B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to a protein modified with a glycosaminoglycan. More particularly, it relates to a protein modified with a glycosaminoglycan which is obtained by reacting a glycosaminoglycan activated with a specific activator with a protein.
  • proteins produced by genetic engineering suffer from a problem of the deficiency of a sugar chain, which seriously affects the stability in vivo .
  • polysaccharides include agarose, carboxymethyl cellulose, dextran (T.P. King, L. Kochoumian, K. Ishizaka, L. Kichtenstein, P.S. Norman: Arch. Biochem. Biophys., 169 , 464 - 473 (1975)), pullulan (M.
  • U.S. Patent 4,485,754 proposes a stabilized protein which is obtained by reacting a protein such as superoxide dismutase or insulin with chondroitin sulfate in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.
  • the protein thus obtained is in the form of a complicated polymer involving a polymer of the protein per se , since plural carboxyl groups in aspartic acid or glutamic acid contained in the protein are activated by 1-enthyl-3-(3-dimethylaminopropyl)carbodiimide, respectively.
  • this product should be further improved from the viewpoint of the pharmacological effect of the unmodified superoxide dismutase or insulin as a monomer.
  • An object of the present invention is to provide a glycosaminoglycan-modified protein, which is highly stable in vivo and can express the inherent physiological effect of the starting protein for a prolonged period of time without forming any polymer of a complicated structure.
  • glycosaminoglycan-modified protein obtained by reacting glycosaminoglycan activated by reducing terminal residue-limiting oxidation method, carboxyl group-activating method, reducing terminal residue-lactonization method or cyanogen bromide activation method with a protein.
  • a glycosaminoglycan-modified protein wherein an amino group of a protein is bound to an aldehyde group, which has been formed by reducing and partially oxidizing the reducing terminal sugar moiety of a glycosaminoglycan is provided.
  • a glycosaminoglycan-modified protein wherein at least some of carboxyl groups in the uronic acid moiety of a glycosaminoglycan are bound to a protein via an amide bond is provided.
  • Figs. 1 to 6 show each an electrophoretic pattern of the glycosaminoglycan-modified protein obtained in Examples and a mixture of a glycosaminoglycan and a protein.
  • Lane 1 stands for the electrophoretic pattern of a mixture of bovine-derived catalase and hyaluronic acid (HA) the reducing terminal residue of which was limitedly oxidized (O-HA) and Lane 2 stands for the pattern of HA-modified bovine-derived catalase.
  • Lane 1 stands for the electrophoretic pattern of a mixture of Aspergillus niger -derived catalase and O-HA and Lane 2 stands for the pattern of HA-modified Asperugillus niger -derived catalase.
  • Lane 1 stands for the electrophoretic pattern of a mixture of uricase and O-HA and Lane 2 stands for the pattern of HA-modified uricase.
  • Lane 1 stands for the electrophoretic pattern of a mixture of asparaginase and O-HA and Lane 2 stands for the pattern of HA-modified asparaginase.
  • Lane 1 stands for the electrophoretic pattern of a mixture of superoxide disumutase (SOD) and chondroitin sulfate derived from bovine tracheal cartilages the reducing terminal residue of which was limitedly oxidized (O-CS(T)) and Lane 2 stands for the pattern of CS(T)-modified SOD (Lot No. 121-2).
  • SOD superoxide disumutase
  • O-CS(T) chondroitin sulfate derived from bovine tracheal cartilages the reducing terminal residue of which was limitedly oxidized
  • Lane 2 stands for the pattern of CS(T)-modified SOD (Lot No. 121-2).
  • Lane 1 stands for the electrophoretic pattern of SOD derived from bovine red blood cell
  • Lane 2 stands for the pattern of SOD derived from dog red blood cell
  • Lane 3 stands for the pattern of HA-modified SOD derived from dog red blood cell
  • Lane 4 stands for HA-modified SOD derived from bovine red blood cell.
  • Fig. 7 shows an electrophoretic pattern of chondroitin sulfate described in Comparative Example.
  • Lane S stands for CS(T)
  • Lanes 1, 2, 3, 4, 5, 6 and 7 each stands for SOD treated with 0.0436 mg, 0.145 mg, 0.436 mg, 1.45 mg, 4.36 mg, 14.5 mg and 43.6 mg of water-soluble carbodiimide (WSC), respectively
  • Lane 8 stands for SOD treated with 43.6 mg of WSC and 0.1 N sodium hydroxide.
  • Fig. 8 is chromatograms of gel filtration referred to in Comparative Example.
  • A is a chromatogram for a mixture of chondroitin sulfate originating from bovine tracheal cartilages and superoxide dismutase, B for the product of the lot No. B, C for the product of the lot No. C and D for the product of the lot No. 121-2 prepared in Example 2.
  • the glycosaminoglycan-modified protein of the present invention may be produced by, for example, reacting a glycosaminoglycan activated by reducing terminal residue-limiting oxidation method, reducing terminal residue-lactonization method, carboxyl group activating method or cyanogen bromide activation method with a protein.
  • glycosaminoglycan-modified protein of the present invention is described in detail below.
  • This method comprises reducing and partially oxidizing the reducing terminal sugar moiety of a glycosaminoglycan to thereby cleave said terminal sugar moiety and form an aldehyde group and producing a protein modified with the glycosaminoglycan by the reducing alkylation reaction between the aldehyde group and an amino group of the protein.
  • the reaction scheme of this method is as follows:
  • R1 and R2 each represents groups commonly observed at the 2- and 5-positions of the reducing terminal sugar moiety of a glycosaminoglycan and examples of R1 include OH, NH2 and NHCOCH3 while examples of R2 include CH2OH, COOH and CH2OSO3M, wherein M represents a hydrogen atom, an alkali or alkaline earth metal or an amine such as trialkylamine or pyridine; and P, n and GAG are as defined above.
  • the glycosaminoglycan of the above formula (IV) is first reduced to thereby cleave the reducing terminal sugar moiety thereof.
  • the compound of the formula (V) is obtained.
  • the reducing agent to be used in this reduction step include alkali boron hydrides such as sodium boron hydride and sodium boron cyanohydride.
  • the above reduction may be effected in an appropriate liquid medium, for example, a buffer solution such as borate buffer solution (pH 8.3), phosphate buffer solution (pH 8.6) or a mixture of such a buffer solution with an organic solvent such as dimethylformamide, acetonitrile or dioxane methanol usually at a temperature of from 0 to 40 °C, preferably from 15 to 20 °C.
  • a buffer solution such as borate buffer solution (pH 8.3), phosphate buffer solution (pH 8.6) or a mixture of such a buffer solution with an organic solvent such as dimethylformamide, acetonitrile or dioxane methanol usually at a temperature of from 0 to 40 °C, preferably from 15 to 20 °C.
  • the amount of the above-mentioned reducing agent may vary depending on the type. It may be used in an amount of from 5 to 50 equivalents, preferably from 10 to 20 equivalents, per mole of the compound of the formula (IV).
  • the compound of the formula (V) thus obtained is partially oxidized.
  • R1 in the formula (V) is an OH group
  • an aldehyde compound of the formula (VI) is formed by this oxidation.
  • R2 in the formula (V) is a CH2OH group
  • an aldehyde compound of the formula (VII) is formed.
  • the oxidizing agent to be used in this oxidation include alkali periodates such as sodium periodate or potassium periodate.
  • the oxidizing agent may be employed usually in an amount of from 1 to 30 equivalents, preferably from 5 to 10 equivalents, per one mole of the compound of the formula (V).
  • the above-mentioned oxidation may be conducted generally at a temperature of from 0 to 20 °C, preferably from 0 to 5 °C.
  • the aldehyde compound of the formula (VI) or (VII) thus obtained may be reacted with an amino group of a protein by a known reducing alkylation method.
  • the desired glycosaminoglycan-modified protein of the present invention represented by the formula (I) or (II) may be obtained.
  • the reducing alkylation may be conducted by reacting the aldehyde compound of the formula (VI) or (VII) with the protein in a liquid medium selected from, for example, the above-mentioned ones usually at a temperature of from 15 to 60 °C. Simultaneously with this reaction or after the completion the reaction, the reaction mixture is subjected to reduction with a reducing agent such as sodium boron cyanohydride.
  • n may generally range from an integer of 1 to 100, preferably from 1 to 10 on average.
  • This method comprises partially oxidizing the reducing terminal sugar moiety of a glycosaminoglycan to thereby cleave the terminal sugar moiety followed by forming a lactone. Then, a protein modified with the glycosaminoglycan is prepared by reacting the lactone with an amino group of the protein.
  • the reaction scheme of this method is as follows:
  • A represents a potassium or sodium atom; and P, n, GAG, R1 and R2 are as defined above.
  • the glycosaminoglycan of the formula (IV) is first oxidized to cleave the reducing terminal sugar moiety.
  • a carboxyl compound of the formula (VIII) is obtained.
  • the oxidizing agent to be used in this oxidation step include iodine and bromine.
  • the oxidizing agent may be used usually in an amount of from 2 to 20 equivalents, preferably from 5 to 15 equivalents, per mole of the compound of the formula (IV).
  • the oxidation reaction may be conducted in a liquid medium selected from among, for example, the above-mentioned ones at a temperature of from 0 to 40 °C, preferably from 15 to 20 °C.
  • potassium hydroxide or sodium hydroxide is added to the reaction mixture to decompose the remaining oxidizing agent.
  • the thus-obtained solution containing the compound of the formula (VIII) is applied to a column packed with 200 ml of strongly acidic cation exchange resins such as Dowex 50 and Amberlite IR120 and allowed it to pass through the column over 1 hour to obtain the passed-through fraction.
  • the column is washed with water, this water fraction is combined with the above-obtained passed-through fraction and then the combined fraction is allowed to stand overnight at 4 °C to form the lactone compound of the formula (IX).
  • the lactone compound of the formula (IX) thus obtained is then reacted with a protein to give the glycosaminoglycan-modified protein represented by the formula (III).
  • the reaction between the lactone compound of the formula (IX) and the protein may be conducted by reacting the lactone in the form of a trialkylamine or adjusting the pH value of a mixture of the lactone and the protein to 4 to 7 with an aqueous solution of sodium hydroxide followed by effecting the reaction at 0 to 70 °C, preferably 15 to 50 °C.
  • n may generally range from an integer of 1 to 100, preferably from 1 to 10 on average.
  • glycosaminoglycans carry each an uronic acid moiety represented by the following formula:
  • the protein modified with the glycosaminoglycan can be obtained by binding a carboxyl group in the uronic acid moiety of a glycosaminoglycan to an amino group of the protein.
  • This method comprises activating a carboxyl group in an uronic acid moiety of a glycosaminoglycan by a method widely known in peptide chemistry and then reacting the carboxyl group thus activated with a protein.
  • the carboxyl group in the uronic acid moiety of the glycosaminoglycan may be activated by, for example, reacting the glycosaminoglycan with a compound selected from N-hydroxysuccinimide, p-nitrophenol, N- hydroxybenzotriazole, N-hydroxypiperidine, N-hydroxysuccinamide and 2,4,5-trichlorophenol to convert the carboxyl group into an active ester group.
  • a compound selected from N-hydroxysuccinimide, p-nitrophenol, N- hydroxybenzotriazole, N-hydroxypiperidine, N-hydroxysuccinamide and 2,4,5-trichlorophenol to convert the carboxyl group into an active ester group.
  • the glycosaminoglycan is converted into a salt with an appropriate amine such as tri(n-butyl)amine, triethylamine, pyridine. Then, the resulting salt is reacted with N-hydroxysuccinimide in an appropriate solvent such as dimethylformamide, pyridine, dimethylsulfoxide in the presence of a condensation agent such as 1-ethyl-3-(dimethylaminopropyl)carbodiimide, dicyclohexylcarbodiimide at a temperature of from 0 to 50 °C.
  • a glycosaminoglycan having an activated carboxyl group is obtained.
  • glycosaminoglycan having an activated carboxyl group is reacted with a protein to give the glycosaminoglycan-modified protein of the present invention.
  • an aqueous solution of the protein is added to an aqueous solution of the glycosaminoglycan having an activated carboxyl group or a phosphate buffer solution (pH 6 to 9) containing the glycosaminoglycan having an activated carboxyl group and the mixture is allowed to react at 0 to 50 °C, preferably 15 to 25 °C, for 30 minutes to 20 hours.
  • the above-mentioned carboxyl group-activating method makes it possible to obtain a glycosaminoglycan-modified protein wherein at least some of carboxyl groups in the uronic acid moiety of the glycosaminoglycan are bound to the protein via an amide bond.
  • This method comprises activating an amino group or a carboxyl group of a protein, or a carboxyl group, a hydroxyl group or an functional group in the reducing terminal residue of a glycosaminoglycan and then allowing the mixture to react to bind the glycosaminoglycan to the protein.
  • glycosaminoglycan-modified protein can be obtained according to this method as follows.
  • Glycosaminoglycan is dissolved in 2 M phosphate buffer (pH 11.5) and an acetonitrile solution of cyanogen bromide is added thereto. After reacting the mixture at 4°C for 5 minutes, acetonitrile is added to the reaction mixture to give a precipitate. After removal of excessive cyanogen bromide, the precipitate is dissolved in 0.1 M sodium hydrogencarbonate solution. A protein was added thereto and a reaction is carried out at 4°C for 20 hours to obtain a desired product.
  • the glycosaminoglycan-modified protein produced by one of the above-mentioned methods may be separated and purified by a conventional method.
  • the reaction mixture is desalted with the use of a dialysis membrane or an ultrafiltration membrane.
  • the desired product is separated from the unreacted glycosaminoglycan and protein and purified with the use of an anion exchanger or a cation exchanger.
  • the product may be separated and purified by gel filtration by taking advantage of the difference in molecular weight.
  • affinity chromatography using a carrier on which an enzyme inhibitor, a substrate or an antibody is immobilized.
  • the glycosaminoglycan employed in the present invention for modifying a protein may be selected over a wide range depending on the required characteristics of the desired glycosaminoglycan-modified protein and the purpose of the modification, without particular restriction. More particularly, it may be selected from among coromic acid, hyaluronic acid, chondroitin, chondroitin sulfate, teichuronic acid, dermatan sulfate, heparin, heparan sulfate, keratosulfate, keratopolysulfate and derivatives thereof such as chondroitin polysulfate.
  • glycosaminoglycans are chondroitin sulfate, chondroitin polysulfate, heparin, heparan sulfate and dermatan sulfate.
  • hyaluronic acid, dermatan sulfate and chondroitin sulfate are suitable for the production of an antirheumatic agent and an antiinflammatory agent.
  • These glycosaminoglycans can be used alone or in combination of two or more.
  • the protein to be modified with the glycosaminoglycan is not particularly restricted.
  • the proteins are physiologically active proteins originating from various animals including human, microorganisms and plants as well as those produced by chemical synthesis or using genetic engineering techniques.
  • Specific examples of the proteins include cytokines (for example, various interferons such as interferon- ⁇ , interferon- ⁇ and interferon- ⁇ , interleukin-2, interleukin-3), hormones [for example, insulin, growth hormone-releasing factor (GRF), calcitonin, calcitonin gene-relating peptide (CGRP), atrial natriuretic hormone (ANP), vasopressin, corticotropin-releasing factor (CRF), vasoactive intestinal peptide (VIP), secretin, ⁇ -melanocyte-stimulating hormone ( ⁇ -MSH), adrenocorticotropic hormone (ACTH), cholecystokinin (CCK), glucagon, parathyroid hormone (PTH), parat
  • a glycosaminoglycan residue is chemically bound to a protein.
  • the amount of the glycosaminoglycan to be introduced into the protein may vary depending on, for example, the protein and/or glycosaminoglycan, its molecular weight and the final usage of the formed glycosaminoglycan-modified protein.
  • the suitable introduction amount of each glycosaminoglycan may be easily determined by those skilled in the art by simple experiments.
  • the glycosaminoglycan may be introduced into the protein in an amount of from 1 to 99.9 % by weight, preferably from 90 to 95 % by weight, based on the weight of the protein to be modified.
  • a glycosaminoglycan-modified protein hardly react with the antibody corresponding to the unmodified protein. Furthermore, the antibody productivity of the protein is substantially lowered by the modification as described in the following Examples.
  • the glycosaminoglycan-modified protein when administered to a living organism, its activity is sustained for a long time, compared with the activity of the corresponding unmodified protein. Thus, the glycosaminoglycan-modified protein shows an improved stability in vivo .
  • Drugs containing the glycosaminoglycan-modified protein of the present invention may be formulated into various forms for oral administration, for example, granules, fine subtilaes, powders, tablets, capsules, syrups, troches, suspensions or solutions.
  • the glycosaminoglycan-modified protein may be orally administered as such.
  • it may be formulated into injections for intravenous, intra-arterial, intraportal, intrapleuroperitoneal, intramuscular, subcutaneous or intratumor administration.
  • it may be in the form of a powder and formulated into an injection upon use. It may be formulated into suppositories for per rectum or ointments for parenteral administration.
  • preparations may be formulated together with known organic or inorganic liquid or solid pharmaceutical carriers, diluents, binders, disintegrating agents and the like suitable for oral, parenteral or per rectum administration.
  • suitable for oral, parenteral or per rectum administration e.g., lactose, sucrose, glucose, starch, gum arabic, tragacanth gum.
  • stabilizers, humectants, emulsifiers, aromatics and components for varying osmotic pressure may be added thereto. Examples thereof include gelatin, glycerol, vaseline, wax, plastics and higher alcohol.
  • salts may be optionally used as an assistant ingredient for maintaining the pH value of the formulation at an appropriate level.
  • a water-soluble or hydrophilic base such as macrogol or an oily base such as cacao oil may be used.
  • the dose of the glycosaminoglycan-modified protein of the present invention may vary depending on the disease to be treated and symptoms and age of the patient. It is preferable to continuously or intermittently administer the compound to a patient in a dose of from 1 to 5000 mg/day in the case of oral administration or from 1 to 100 mg/day in the case of injection.
  • the activity and molecular weight of the GAG-modified proteins and the content of glycosaminoglycans and proteins were determined under the following conditions.
  • One unit (U) of enzyme is defined as the amount of the enzyme decomposing 1.0 ⁇ M of hydrogen peroxide in a hydrogen peroxide solution having a hydrogen peroxide concentration ranging from 9.2 to 10.3 mM per minute at pH 7.0 and 25 °C.
  • One unit of enzyme is defined as the amount of the enzyme that produced a decrease in absorbance of 0.001 of a suspension of a gram-positive bacterium (ML-Cell) at 540 nm per minute at pH 6.2 and 35 °C.
  • One unit of enzyme is defined as the amount of the enzyme liberating 1 ⁇ M of an unsaturated disaccharide from hyaluronic acid per minute at pH 6.2 and 37 °C.
  • One unit of enzyme is defined as the amount of the enzyme hydrolyzing 1 ⁇ M of N-acetyl-tri-L-alanine methyl ester per minute at pH 8.5 and 25 °C.
  • One unit of enzyme is defined as the amount of the enzyme oxidizing 1 ⁇ M of uric acid per minute at pH 8.5 and 25 °C.
  • One unit of enzyme is defined as the amount of the enzyme that produced a plasminogen, when plasminogen is treated with urokinase at pH 7.5 and 37 °C, which gives a change of 1.0 of an absorbance of a substance soluble in perchloric acid formed from ⁇ -casein per minute at ⁇ 275.
  • One unit of enzyme is defined as the amount of the enzyme producing 1.0 ⁇ M of ammonia from L-aspargine per minute at pH 8.6 and 37 °C.
  • One unit of enzyme is defined as the amount of the enzyme inhibiting 50 % of the activity of xanthine oxidase at pH 7.8 and 25°C.
  • a sample is subjected to high performance liquid chromatography using a G6000PWx2 (Tosoh Corporation) column. Elution was carried out with a 0.2 M sodium chloride aqueous solution. The molecular weight of a sample is determined based on a calibration curve.
  • a sample is subjected to carbazole-sulfuric acid reaction in accordance with the method as described in T. Bitter and H. M. Muir, Analytical Biochemistry, 4 , 330-334 (1962).
  • the content of a protein is determined by the method of Lowry et al. as described in O. H. Lowry, N. J. Rosenbrough, A. L. Farr and R. J. Randall, J. Biol. Chem., 193 , 265-275 (1951).
  • Hyaluronic acid [originating from comb: HA100 (MW 1,000,000)], chondroitin sulfate [originating from bovine tracheal cartilages: CS(T), shark cartilages: CS(S), whale cartilages: CS(W)], dermatan sulfate (originating from pig skin: DS), heparin (originating from pig intestinum um um: Hep) and heparan sulfate (originating from pig kidney: HS) were treated in the same manner as in the above step A under the conditions as specified in Table 1. Thus reducing terminal residue-opened glycosaminoglycans (R-GAGs) were obtained.
  • O-GAGs reducing terminal residue-limiting oxidized glycosaminoglycans
  • Acetylcellulose membrane (SEPARAX, JOOKOO Co., Ltd.) 0.1 M formic acid/pyridine (pH 3.0) 0.5 mA/cm, 30 min. and
  • P2 is a catalase residue exclusive of 26 amino groups, on an average, from catalase and X is as defined above.
  • Uricase content 1.8 %.
  • Hyaluronic acid content 98.2 %.
  • Acetylcellulose membrane SEPARAX, JOOKOO Co., Ltd.
  • 0.1 M formic acid/pyridine pH 3.0
  • P3 is a uricase residue exclusive of 5.5 amino groups, on an average, from uricase and X is as defined above.
  • Catalase originating from bovine liver, superoxide dismutase originating from bovine erythrocyte, hyaluronidase originating from bovine testis, lysozyme originating from albumen (the above enzymes are all manufactured by Seikagaku Corporation) and urokinase originating from human renal cell (Kyowa Hakko Kogyo Co., Ltd.) were modified with the products of lot Nos. 111 to 116 in the same manner as in the above step I under the conditions specified in Table 3.
  • Table 4 shows the analytical data of the products thus obtained.
  • Fig. 5 shows the electrophoretic pattern of the product of lot No. 121-1 as a representative. The electrophoresis was conducted under the same conditions as those described in I.
  • Catalase or HA-catalase dissolved in a 0.05 M phosphate buffer solution of pH 7.0 (hereinafter abbreviated as PBS) was intraperitoneally (hereinafter abbreviated as i.p.) administered once a week for 12 weeks to female Swiss-Webster mice (each group has 4 animals) in a dose of 0.1 mg in terms of protein.
  • PBS phosphate buffer solution of pH 7.0
  • the titer of each serum was determined by HPO-ELISA (enzyme-linked immunosorbent assay with the use of horseradish peroxidase) in accordance with the method of Voller et al.
  • 100 ⁇ l of an antigen solution diluted with a carbonate buffer solution (0.5 M, pH 9.5) to 10 ⁇ g/ml was used to inoculate wells of the Nunc Immuno II microtiter plates. The plate were incubated at 4°C overnight and then washed with a physiological saline containing 0.05% of Tween 20 thrice.
  • 100 ⁇ l of a test serum diluted with the Tween 20-containing PBS was added to each well.
  • mice serum control Three controls, i.e., an antigen control, an antiserum control and a normal mouse serum control were also prepared. After allowing to stand at room temperature for 1 hour, 100 ⁇ l portions of HPO-conjugated goat anti-mouse immunoglobulins (IgG + IgA + IgM) were added to each well and incubated at room temperature for 1 hour and 30 minutes. 100 ⁇ l of o-phenylenediamine substrate was added to each well and incubated for 10 minutes. Next, 0.01 ml of 4 N sulfuric acid was added to cease the reaction. The titer is expressed in the antibody dilution ratio giving an optical density of 0.01 based on the control serum.
  • HPO-conjugated goat anti-mouse immunoglobulins IgG + IgA + IgM
  • the antigenicity or immunogenicity of HA-catalase is lower than that of unmodified catalase.
  • a ddy male mouse aged 8 weeks is kept in a keeping device and the right hind leg is tied around with a suture (Brain No. 2). One end of the suture is fixed while a weight of 500 g is suspended from another end of the suture.
  • ischemia is conducted for a definite period of time. Before the ischemia and 60 minutes thereafter, the thickness of the foot-pad of the animal was measured with slide calipers. Then, the foot-pad is cut and weighed.
  • a physiological saline is intravenously administered immediately before the initiation of the ischemia.
  • specimen shown in Table 6 was administered 30 minutes before the initiation of the ischemia and immediately before the same. Each group has 5 animals.
  • the catarase used as a specimen was originated from bovine liver.
  • the HA-catalase used was prepared as follows. 10 mg of the HA-catalase of lot No. 120-1 was dissolved in 5.2 ml of a physiological saline and filtered through a membrane of 0.22 ⁇ m (Milex GV; mfd. by Nippon Millipore Kogyo K.K.). 1 ml portions of the filtrate were distributed to ampuls to give a preparation for injection. The preparation contained 600 U of the enzyme per ampul.
  • Chondroitin sulfate [originating from bovine tracheal cartilages: CS(T), shark cartilages: CS(S), whale cartilages: CS(W)], heparin (originating from swine intestinum ***: Hep), heparan sulfate (originating from swine kidney: HS) and dermatan sulfate (originating from swine skin DS) were treated in the same manner as in the above step I under the conditions as specified in Table 7. The thus-obtained products are shown in Table 7.
  • P7 is a superoxide dismutase residue exclusive of 80 amino groups, on an average, from superoxide dismutase
  • Y' is a hydrogen atom of the reducing terminal residue of chondroitin sulfate
  • the sum of n, m and l is 40 and X' R3 and R4 are as defined above.
  • hyaluronic acid 500 mg was dissolved in 50 ml of water. 5 ml of a 0.1 M iodine solution in methanol was added thereto and the resulting mixture was allowed to react at room temperature for 6 hours. Then, approximately 5 ml of 0.1 N potassium hydroxide was added to the reaction mixture so as to cause the discoloration of the liberated iodine. Ethanol saturated with potassium acetate was added to the solution. The precipitate thus formed was collected by filtration and dissolved in 50 ml of water. The resulting solution was contacted with 50 ml of a strongly acidic ion exchange resin [Dowex 50(H+)] at 5 °C for 20 hours.
  • a strongly acidic ion exchange resin [Dowex 50(H+)]
  • hyaluronic acid-modified RGDV The characteristics of hyaluronic acid-modified RGDV were as follows: Lot No. 320. Yield: 40.2 mg. RGDV content: 3.3 %. Hyaluronic acid content: 96.7 %. and In the above formulae, X is as defined above.
  • comb-derived hyaluronic acid 400 mg was dissolved in 2 M phosphate buffer (pH 11.5) and 1 ml of an acetonitrile solution of cyanogen bromide (100 mg/ml) was added thereto to allow the resulting mixture to react at 4°C for 5 minutes. Immediately after the termination of the reaction, 150 ml of acetonitrile was added to the reaction mixture to form precipitate. The thus-obtained precipitate was washed quickly with acetonitrile and was dissolved in 0.1 M sodium hydrogencarbonate solution.
  • the characteristics of the hyaluronic acid-modified SOD thus obtained were as follows. Yield: 350 mg SOD content: 21.2% Hyaluronic acid content: 78.8% Molecular weight: 172,000 Activity: 82.1% of that of unmodified SOD Electrophoresis: cf. Fig. 6.
  • the activity of the WSC-modified SOD is lower than the glycosaminoglycan-modified SOD of the present invention, though the contents of SOD are the same as each other.
  • WSC method (lot No. B): 44.4 % of the activity of unmodified SOD.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
EP90119607A 1990-03-30 1990-10-12 Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten Expired - Lifetime EP0454898B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP81163/90 1990-03-30
JP2081163A JP2975632B2 (ja) 1990-03-30 1990-03-30 グリコサミノグリカン修飾プロテイン

Publications (2)

Publication Number Publication Date
EP0454898A1 true EP0454898A1 (de) 1991-11-06
EP0454898B1 EP0454898B1 (de) 1996-03-13

Family

ID=13738789

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90119607A Expired - Lifetime EP0454898B1 (de) 1990-03-30 1990-10-12 Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten

Country Status (12)

Country Link
US (1) US5310881A (de)
EP (1) EP0454898B1 (de)
JP (1) JP2975632B2 (de)
KR (1) KR100188382B1 (de)
AT (1) ATE135375T1 (de)
AU (1) AU649416B2 (de)
CA (1) CA2027447A1 (de)
DE (1) DE69025920T2 (de)
DK (1) DK0454898T3 (de)
ES (1) ES2083989T3 (de)
FI (1) FI102836B1 (de)
NO (1) NO179044C (de)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022331A1 (en) * 1991-06-06 1992-12-23 The School Of Pharmacy Pharmaceutical compositions
EP0562624A2 (de) * 1992-03-26 1993-09-29 Modrovich, Ivan E. Stabilisierung von funktionellen Proteinen
EP0686397A2 (de) * 1994-05-09 1995-12-13 Boehringer Mannheim Gmbh Verwendung von Chondroitin Sulphate Protoglycanen zum Neuronalschutz
EP0693499A1 (de) * 1994-07-22 1996-01-24 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Gel auf Basis eines Derivat von Glykosaminoglykan; Copolymers aus Acrylamid und diesem Derivat; Verfahren zum Nachweis von Enzymen
GB2266239B (en) * 1992-03-25 1996-03-06 Jevco Ltd Wound healing compositions containing chondroitin sulphate oligosaccharides
WO1996009805A2 (en) * 1994-09-23 1996-04-04 Zonagen, Inc. Chitosan induced immunopotentiation
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
WO2005016974A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
WO2006090119A1 (en) 2005-02-23 2006-08-31 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
EP1886696A1 (de) * 2006-08-03 2008-02-13 Endotis Pharma Konjugate von antithrombin-bindende-oligosaccharid-derivate und therapeutische proteine

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502550B1 (de) * 1991-03-07 1995-01-04 Mect Corporation Colominsäure und Produkte einer teilweisen Hydrolyse von Colominsäure zur Herstellung von Arzneimitteln zur Behandlung von Hepatitis, Nephritis und Arthritis
AU711535B2 (en) * 1994-02-23 1999-10-14 Kyowa Hakko Kirin Co., Ltd. Platelet growth accelerator
US5677276A (en) * 1994-12-23 1997-10-14 La Jolla Cancer Research Foundation Immobilization of peptides to hyaluronate
CA2232527C (en) * 1995-09-19 2008-09-02 Seikagaku Corporation Anti-inflammatory agent
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
JP2001502052A (ja) * 1996-09-25 2001-02-13 ユニバーサル ヘルスウォッチ，インコーポレーテッド 液体移動および干渉に対する抵抗を改良した診断用検査デバイス
WO2001005434A2 (en) * 1999-07-20 2001-01-25 Amgen Inc. Hyaluronic acid-protein conjugates
EP2292271A3 (de) * 2001-10-10 2011-09-14 BioGeneriX AG Neumodulierung und Glykokonjugation von Antikörpern
ZA200700168B (en) * 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
JP2006516534A (ja) 2002-09-11 2006-07-06 フレセニウス・カビ・ドイッチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｈａｓ化ポリペプチド、特にｈａｓ化エリスロポエチン
CA2499872C (en) * 2002-09-25 2015-11-17 Johns Hopkins University School Of Medicine Cross-linked polymer matrices, and methods of making and using same
US8673333B2 (en) * 2002-09-25 2014-03-18 The Johns Hopkins University Cross-linked polymer matrices, and methods of making and using same
US7862831B2 (en) * 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
WO2006089119A2 (en) * 2005-02-18 2006-08-24 Cartilix, Inc. Biological adhesive
US8658593B2 (en) 2011-06-06 2014-02-25 The Cleveland Clinic Foundation Treatment of extracellular matrix to reduce inflammation
WO2015046602A1 (ja) 2013-09-30 2015-04-02 生化学工業株式会社 タンパク質の血中滞留性の増強方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081853A1 (de) * 1981-12-15 1983-06-22 Sentron v.o.f. Komplex von Antikoagulierungsmittel und Protein
EP0242416A1 (de) * 1986-04-22 1987-10-28 Valcor Scientific, Ltd. Verfahren zur Stabilisierung von Proteinen
EP0265865A2 (de) * 1986-10-28 1988-05-04 B. Braun Melsungen AG Blutersatzmittel
WO1989009624A1 (en) * 1986-06-27 1989-10-19 Cetus Corporation Solubilization of proteins for pharmaceutical compositions
EP0344068A1 (de) * 1988-05-24 1989-11-29 Elf Sanofi N-Polyosyl-Polypeptide
EP0345616A2 (de) * 1988-06-04 1989-12-13 Hoechst Aktiengesellschaft Hirudin-Derivate mit verzögerter Wirkung
WO1990001332A1 (en) * 1988-08-10 1990-02-22 Cetus Corporation Plasminogen activator-heparin conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824092A (en) * 1955-01-04 1958-02-18 Robert E Thompson Process of preparation of a gelatincarboxymethyl cellulose complex
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4301153A (en) * 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
CA1171375A (en) * 1980-09-15 1984-07-24 Ulf P.F. Lindahl Oligosaccharides having selective anticoagulation activity
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4526714A (en) * 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
SE8200751L (sv) * 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
US4585754A (en) * 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US4863907A (en) * 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081853A1 (de) * 1981-12-15 1983-06-22 Sentron v.o.f. Komplex von Antikoagulierungsmittel und Protein
EP0242416A1 (de) * 1986-04-22 1987-10-28 Valcor Scientific, Ltd. Verfahren zur Stabilisierung von Proteinen
WO1989009624A1 (en) * 1986-06-27 1989-10-19 Cetus Corporation Solubilization of proteins for pharmaceutical compositions
EP0265865A2 (de) * 1986-10-28 1988-05-04 B. Braun Melsungen AG Blutersatzmittel
EP0344068A1 (de) * 1988-05-24 1989-11-29 Elf Sanofi N-Polyosyl-Polypeptide
EP0345616A2 (de) * 1988-06-04 1989-12-13 Hoechst Aktiengesellschaft Hirudin-Derivate mit verzögerter Wirkung
WO1990001332A1 (en) * 1988-08-10 1990-02-22 Cetus Corporation Plasminogen activator-heparin conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 103, no.21, 25th November 1985, page 45, abstract no. 171707k, Columbus Ohio, US; A.V. MAKSIMENKO et al.: "Water-soluble urokinase conjugates: fibrinolytic activity and other properties", & VOPR. MED. KHIM. 1985, 31(4), 12-20 *
JOURNAL OF CONTROLLED RELEASE, vol. 12, no. 1/3, January 1990, pages 149-156, Elsevier Science Publishers B.V., Amsterdam, NL; T. FUJITA et al.: "Alteration of biopharmaceutical properties of drugs by their conjugation with water-soluble macromolecules: uricase-dextran conjugate" *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022331A1 (en) * 1991-06-06 1992-12-23 The School Of Pharmacy Pharmaceutical compositions
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB2266239B (en) * 1992-03-25 1996-03-06 Jevco Ltd Wound healing compositions containing chondroitin sulphate oligosaccharides
EP0562624A2 (de) * 1992-03-26 1993-09-29 Modrovich, Ivan E. Stabilisierung von funktionellen Proteinen
EP0562624A3 (en) * 1992-03-26 1994-10-05 Modrovich Ivan Endre Stabilization of functional proteins
EP0686397A3 (de) * 1994-05-09 1998-10-28 Boehringer Mannheim Gmbh Verwendung von Chondroitin Sulphate Protoglycanen zum Neuronalschutz
EP0686397A2 (de) * 1994-05-09 1995-12-13 Boehringer Mannheim Gmbh Verwendung von Chondroitin Sulphate Protoglycanen zum Neuronalschutz
EP0693499A1 (de) * 1994-07-22 1996-01-24 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Gel auf Basis eines Derivat von Glykosaminoglykan; Copolymers aus Acrylamid und diesem Derivat; Verfahren zum Nachweis von Enzymen
US6228998B1 (en) 1994-07-22 2001-05-08 Seikagaku Kogyo Kabushiki Kaisha Amino spacered glycosaminoglycan derivatives and their use in copolymerization with acrylamide
WO1996009805A2 (en) * 1994-09-23 1996-04-04 Zonagen, Inc. Chitosan induced immunopotentiation
AU688603B2 (en) * 1994-09-23 1998-03-12 Zonagen, Inc. Chitosan induced immunopotentiation
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
WO1996009805A3 (en) * 1994-09-23 1996-07-25 Zonagen Inc Chitosan induced immunopotentiation
US8653255B2 (en) 2003-08-12 2014-02-18 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
WO2005016949A2 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives
WO2005016949A3 (en) * 2003-08-12 2005-03-31 Lipoxen Technologies Ltd Sialic acid derivatives
US7807824B2 (en) 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
KR101113726B1 (ko) * 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
WO2005016974A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US9452224B2 (en) 2003-08-12 2016-09-27 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US10406209B2 (en) 2003-08-12 2019-09-10 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
WO2006090119A1 (en) 2005-02-23 2006-08-31 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
EP3138855A1 (de) 2005-02-23 2017-03-08 Lipoxen Technologies Limited Aktivierte sialinsäurederivate für die derivatisierung und konjugation von proteinen
EP1886696A1 (de) * 2006-08-03 2008-02-13 Endotis Pharma Konjugate von antithrombin-bindende-oligosaccharid-derivate und therapeutische proteine
WO2008029278A2 (en) * 2006-08-03 2008-03-13 Endotis Pharma S.A. Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
WO2008029278A3 (en) * 2006-08-03 2008-11-20 Endotis Pharma S A Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins

Also Published As

Publication number Publication date
NO904378L (no) 1991-10-01
DK0454898T3 (da) 1996-04-15
KR910016770A (ko) 1991-11-05
EP0454898B1 (de) 1996-03-13
FI102836B (fi) 1999-02-26
FI102836B1 (fi) 1999-02-26
FI905003A (fi) 1991-10-01
KR100188382B1 (ko) 1999-06-01
ES2083989T3 (es) 1996-05-01
CA2027447A1 (en) 1991-10-01
NO179044C (no) 1996-07-24
AU649416B2 (en) 1994-05-26
JPH03284698A (ja) 1991-12-16
US5310881A (en) 1994-05-10
ATE135375T1 (de) 1996-03-15
AU6450690A (en) 1991-10-31
DE69025920T2 (de) 1996-08-14
JP2975632B2 (ja) 1999-11-10
DE69025920D1 (de) 1996-04-18
NO904378D0 (no) 1990-10-10
NO179044B (no) 1996-04-15
FI905003A0 (fi) 1990-10-11

Similar Documents

Publication Publication Date Title
US5310881A (en) Glycosaminoglycan-modified protein
JP2514950B2 (ja) 化学修飾蛋白質，その製造法および中間体
RU2432175C2 (ru) N-концевое полисиалилирование
US5342940A (en) Polyethylene glycol derivatives, process for preparing the same
US5932462A (en) Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5286637A (en) Biologically active drug polymer derivatives and method for preparing same
US5066590A (en) Superoxide dismutase combined with a poly(alkylene oxide)
AU675798B2 (en) Low diol polyalkylene oxide biologically active proteinaceous substances
BG65046B1 (bg) Метод за степенно прикрепване на полиетиленгликолкъм полипептид
EP0400472A2 (de) Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine.
JPH07508727A (ja) 生体分子と結合したポリオキシメチレン−オキシエチレン共重合体
JPH0676439B2 (ja) 化学修飾ペプチドホルモンおよびその製造法
WO1982003394A1 (en) Therapeutically active compound and pharmaceutical composition containing the same
US4022888A (en) Esterified orgotein
JPH0585942A (ja) インターフエロン−ヒアルロン酸及び／又はその塩の結合体
JP2766303B2 (ja) グリコサミノグリカンで修飾されたスーパーオキシドジスムターゼ及びその製造法
JPH02238879A (ja) Ｎ―ポリオシル―ポリペプチド
JP2931622B2 (ja) ポリエチレングリコール誘導体を得る製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19920113

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEIKAGAKU KOGYO KABUSHIKI KAISHA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPOR

17Q First examination report despatched

Effective date: 19931005

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19960313

Ref country code: BE

Effective date: 19960313

REF Corresponds to:

Ref document number: 135375

Country of ref document: AT

Date of ref document: 19960315

Kind code of ref document: T

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REF Corresponds to:

Ref document number: 69025920

Country of ref document: DE

Date of ref document: 19960418

ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2083989

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19961031

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19980903

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19980916

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19981001

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19981005

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19981014

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19981031

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991012

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991013

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000501

EUG Se: european patent has lapsed

Ref document number: 90119607.1

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20000501

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20031003

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20031008

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20031023

Year of fee payment: 14

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20001113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050503

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20041012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050630

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051012

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE